Physician profile
Kiran Chava
NPI 1629176771
$700.53
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $185 · 2021: $516.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $164.82 | 2020 | |
| Abbvie INC. | $121.61 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $103.06 | 2021 | |
| Novo Nordisk INC | $62.97 | 2021 | |
| Janssen Pharmaceuticals, INC | $47.53 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.08 | 2021 | |
| Biogen, INC. | $43.89 | 2020-2021 | |
| Lilly USA, LLC | $42.60 | 2021 | |
| Amarin Pharma, INC. | $23.38 | 2021 | |
| Merck Sharp & Dohme LLC | $16.04 | 2021 | |
| Amgen INC. | $15.64 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.91 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiran Chava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.